ArticleInfectious diseases and therapy2026
Analysis of the Economic and Public Health Impact of New Immunization Strategies in Infants Against Respiratory Syncytial Virus (RSV) in Colombia.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRespiratory syncytial virus (RSV) infections are a leading cause of lower respiratory tract infections (LRTI), particularly bronchiolitis and pneumonia, leading to significant hospitalizations and economic burden in infants. In Colombia, RSV is endemic with high morbidity and mortality rates, underscoring the need for effective prophylactic technologies to reduce its impact.
methodsThis study aimed to analyze the health and economic impact of new RSV immunization technologies in Colombia, focusing on two interventions: nirsevimab and RSVpreF. A static cohort decision model was used to compare these interventions against the standard of care (palivizumab-SoC), estimating outcomes including hospitalizations, intensive care unit (ICU) admissions, deaths, and event-related healthcare costs. The model included outcomes such as QALYs and direct and indirect event-related costs from the third-party and societal perspectives. Acquisition costs of prophylactic interventions were not included because prices are not publicly available during ongoing negotiations.
resultsNirsevimab was associated with a greater reduction in healthcare events and costs compared to both SoC and RSVpreF. In the base-case scenario, it prevented an additional 44,039 events and was associated with US$23.4 million lower event-related healthcare costs compared to SoC. When compared with RSVpreF, it averted 14,558 more events and was associated with US$8.4 million lower event-related costs. The greatest reduction occurred in primary care visits, with 32,744 and 10,458 fewer cases versus SoC and RSVpreF, respectively, followed by reductions in hospitalizations of 6210 and 2257 cases. Nirsevimab yielded up to 646 additional QALYs compared with RSVpreF and associated with up to US$25.3 million lower event-related costs from avoided health events in societal scenarios. Sensitivity analysis identified nirsevimab efficacy and infection distribution as the key drivers of event-related cost and QALY outcomes.
conclusionNirsevimab was associated with larger reductions in RSV-related events, greater reductions in event-related costs, and higher QALYs than SoC and RSVpreF. Its adoption in national immunization programs could significantly reduce the economic and disease burden of RSV and improve infant health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.